Horizon Therapeutics’ Daxdilimab Phase 2 trial fails to reach primary endpoint in SLE

Horizon Therapeutics plc (Nasdaq: HZNP) announced that its Phase 2 clinical trial studying the efficacy of daxdilimab in the treatment of systemic lupus erythematosus (SLE) ... Read More